Saroglitazar Outcomes Vary by Region in Liver Trial
U.S. patients with primary biliary cholangitis saw better response rates than international peers in a 2026 analysis.
Updated on Oct. 28, 2026 in Allergies
Live Poll
Should medical researchers prioritize studying how patient response to new drugs differs by geographic region?
A 2026 post hoc analysis of the EPICS-III trial indicates that U.S. patients with primary biliary cholangitis may experience greater biochemical response and itch reduction with saroglitazar than international counterparts. Researchers compared outcomes at week 52 to determine if treatment benefits remain consistent across different global populations.
Why it matters
Understanding regional variations in treatment response is critical for clinicians managing complex liver diseases like primary biliary cholangitis. This analysis highlights why standardized global trials require careful investigation into whether patient characteristics or background care affect drug efficacy.
This post hoc analysis of the EPICS-III trial included 42 U.S. participants and 106 non-U.S. participants. At 52 weeks, U.S. participants showed a 60.7% placebo-adjusted biochemical response compared to 41.6% for non-U.S. patients.
The players
EPICS-III trial
A Phase 2b/3 clinical study investigating the efficacy of saroglitazar in patients diagnosed with primary biliary cholangitis.
The details
The analysis evaluated the efficacy of 1 mg saroglitazar, which acts as a dual PPAR alpha and gamma agonist to regulate metabolic pathways. Researchers measured composite biochemical response and alkaline phosphatase (ALP) levels to assess liver function improvement. By comparing median baseline ALP levels of 302 U/L in the U.S. and 287 U/L internationally, the study sought to identify if geographic treatment disparities exist within clinical trials.
Timeline
Week 24: Assessment of 5-D itch score reduction.
Week 52: Assessment of composite biochemical response and ALP normalization.
Health Landscape
This analysis sits within the broader research efforts to optimize saroglitazar as a potential treatment for primary biliary cholangitis. It follows established trends in clinical pharmacology aimed at identifying demographic-specific responses in multi-center international trials.
Patients living with primary biliary cholangitis should consult their gastroenterologist or hepatologist to discuss how recent trial data for saroglitazar compares to their current treatment plan. Any potential changes to therapy or interest in clinical studies are conversations that must be handled by a medical professional.
The takeaway
This analysis suggests that clinical trial outcomes may vary significantly across different international patient populations. When exploring new treatment options for liver conditions, always track your own biochemical markers and discuss relevant study findings with your primary care provider.
Further reading
For broader insight into immune-mediated conditions and current treatment research, visit our Allergies section.
Source note: This article includes information reported by Healio.
Live Poll
Should medical researchers prioritize studying how patient response to new drugs differs by geographic region?
